A roundtable discussion at the 2024 Charing Cross (CX) Symposium (23–25 April, London, UK) saw a multidisciplinary panel of experts discuss a new multimodal treatment for diabetic wounds—AOTI’s topical oxygen therapy (TWO2).
Andrew Boulton (Manchester, UK), professor of medicine at the University of Manchester, was joined in the CX Vascular studio by two vascular surgeons: Anahita Dua (Boston, USA), associate professor at Harvard Medical School, and David Dexter (Norfolk, USA), clinical professor at East Virginia Medical School.
Setting the scene, Boulton outlined the scale of the issue at hand. He noted that more than six million people are affected by a diabetic foot ulcer each year—according to a review recently published in the Journal of the American Medical Association (JAMA)—and went on to describe this “immense” problem as one that disproportionately affects minorities and the poorer population.
These facts left the panel with “much to talk about,” continued Boulton, prompting multidisciplinary care, multimodality therapy, and strong evidence to emerge in the subsequent discussion as non-negotiables for future diabetic wound management.
“We are moving into a new era,” Boulton remarked, when the discussion turned to novel therapies for diabetic wounds. He pointed out that, in 2024, there are now evidence-based and society-endorsed treatments such as TWO2 available, citing in particular the American Diabetes Association’s 2024 A-grade recommendation for this therapy.
TWO2 is applied by the patient at home for 90 minutes five days per week over gas-permeable dressings and, as the panel pointed out, provides multimodal therapy involving oxygen, compression and humidification.
“We’re really hitting kind of a revolution in the way that we manage wounds,” Dua commented, based on her experience with the therapy so far. Dexter also shared positive reviews for TWO2, adding also that the compliance rate to date has been “spectacularly high”.
This video is sponsored by AOTI.
